Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hmm...pre-market not lying.
I keep seeing that Credit Suisse is circling the drain...will mean a tough couple of days or more for the likes of AVXL and any pre-revenue stocks.
If he actually delivers when he promises you've answered your own question.
Funny thing about share price, bas - it's the only thing that pays.
AVXL needs to produce and achieve stated milestones.
It's really not a difficult concept. High-profile coaches who talk about winning, but don't win, get fired. We AVXL investors have been promised a lot in terms of milestones over the years but here we sit with far less than a billion $ MC while pieces of crap like SAVA are actually valued (improperly, I believe) by WS. At this point I far prefer silence from Missling to the muddled communications we've all gotten used to....instead of talking about the work I'd like to see evidence of actually doing the work necessary to get this drug to market.
Obviously. I'm holding shares of an equity whose product (right now) could help millions yet whose market cap is <1% of one of the world's premiere purveyors of cancer (Altria/MO). Thanks, but no further condescension required.
Missling's stance should be moot in BP's eyes, if Anavex truly has what the evidence shows.
Where is the partnership or Joint Venture that he has said many times, he is open to pursuing. How hard is it to pick up a phone once a month, and make a couple calls. Over the course of 5 years, how tough is that to do? Is that so hard, if you have a compound worth billions and billions of dollars? People must be awful dumb in Big Pharma not to see they can make billions and billions of dollars.
This is the line of questioning that torments me about AVXL. There has to be dozens, if not hundreds of highly educated, highly compensated people in BP firms globally whose job is to ferret out those acquisition opportunities that would be potential gold mines for their employers, not to mention their own bonuses. What are they thinking, or not thinking when it comes to a little $600 million MC that supposedly has a game-changing pipeline in its portfolio, that has survived years of safety testing and through multiple trials for different diseases has not yet experienced failure? Too much risk? Seriously? Lilly (for example) is a $300 billion company, other BP giants are similarly capitalized...it all makes no sense me.
'Firing on all cylinders?' Maybe. But it would be helpful to shift from Neutral into Drive.
make use of the ignore button
So what is it with biotech today? Have all drug sales been banned? (Except of course cross-border fentanyl).
Glad to see that the market respected the hiring announcement of the stat guru.
5% drop on 23k shares traded = ZERO demand for our homely little orphan stock...
This stock ought to be ashamed of itself.
Nothing's afoot. Volume is exceptionally pitiful (same yesterday)...this is another week of MM playtime.
$AVNX? What's that?
And yet a $1.05 bill MC...
Note the insane drop RETA had on Monday - from 45 to below 30 within two hours. Would have been gut-wrenching to hold through that chaos.
Some post-lunch cliff diving I see. I hope we avoid the rocks.
Not so. A past event was described ("passing the marshmallow test") leading to a present condition (faster approval process than had failure of the mm test occurred). Where's the proof of that past event being essential to the current approval situation?
I assume you'll reply to this, and yet another pointless Anavex MB argument will proceed. If that is the case, I forfeit in advance.
“Billy has decided to retire from the FDA and explore other opportunities while continuing his focus on improving the lives of patients with neurological diseases,” Peter Stein, head of the Office of New Drugs, said
New record for coffee exiting my nose just occurred
Where's proof of that hypothesis?
The problem is, extra marshmallows won't mean crap when I (and tens of millions of others) have dementia that could have been forestalled or even prevented.
nice week
Lot of play between 100k-200k per year and $1000/mo.
Since when has 'news' not depressed the stock price?
pathetic
It is contended that the biostatistics publicly released from the trials are not complete, so the actual safety and effectiveness of blarcamesine can’t yet be known.
[boldface mine]
And, for all intents and purposes related to a universally terminal and costly (to all involved) disease, these are two irrelevant characteristics
Ought to soon be time for the MM long dog-whistle.
baby seal day for AVXL
The obsession with this dead-end approach has been fanatical, almost cultlike.
There's a lot of that going around these days....
and just like that the buying pressure evaporates, instantly. Amazing.
Very large bid/ask spread this morning. Weird.
It's an exercise in silliness, Joseph.
You've just described life in general, Mcmag...
Much better chance of finishing the week above 10.80 or so, busting above 20- and 50-week moving averages...with a volume bump and a Friday eod close of 11-11.50 there's clearing sailing to around 14... excluding, of course, a sp-derailing PR during the run.
Annovis sp cliff-diving this afternoon after ridiculous no-reason run up.
I'd be completely content with no more PR's except for agency approvals and earnings announcements.
Just a student of history, that's all.
You must be discussing some other stock - certainly not AVXL.